Boundless Bio (BOLD) Announces Pipeline and Leadership Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Boundless Bio Announces Pipeline and Leadership Updates
December 12, 2024 4:01 PM ESTCompany elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial
Third ecDTx program advancing, with plans for development candidate nomination by mid-2025
Operating runway extended into 2027, through anticipated clinical readout for BBI-355 and key development milestones for third ecDTx program
Klaus Wagner, M.D., Ph.D., Chief Medical Officer, and Neil Abdollahian, Chief Business Officer, stepping down; James L. Freddo, M.D., to serve as Interim Chief Medical Officer
SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) --... More



